tbuckley/cabot-search huggingface dataset:
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer
Authors: Paul L. Swiecicki, Emrullah Yilmaz, Ari Joseph Rosenberg, Takao Fujisawa, Justine Yang Bruce, Changting Meng, Michele Wozniak, Yongyun Zhao, Michael Mihm, Jason Kaplan, Seema Gorla, Jessica L. Geiger
Journal: Journal of Clinical Oncology (2024)

PURPOSE Despite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prognosis, and effective treatments are needed. As nectin-4 is widely expressed in HNC, enfortumab vedotin (EV), a nectin-4–directed antibody-drug conjugate, was explored in HNC in EV-202 (ClinicalTrials.gov identifier: NCT04225117 ). METHODS This open-label, multicohort, phase II study evaluated intravenous EV 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle. In the HNC cohort, eligible patients had recurrent/metastatic HNC and had received platinum-based therapy for locally advanced/metastatic disease and a PD-1/PD-L1 inhibitor. The primary end point was investigator-assessed confirmed objective response rate (ORR) per RECIST version 1.1. Secondary end points were investigator-assessed duration of response (DOR), disease control rate (DCR), and progression-free survival (PFS); overall survival (OS); and safety. RESULTS The primary analysis included 46 patients; all received EV (median follow-up, 9.3 months). Most patients (52.2%) had ≥3 previous lines of systemic therapy in the metastatic setting. Confirmed ORR was 23.9%, DCR was 56.5%, and median DOR was not reached (median DOR was 9.4 months at a later data cutoff [median follow-up, 11.3 months]). Median PFS and OS were 3.9 and 6.0 months, respectively. Treatment-related adverse events (TRAEs) occurring in &gt;20% of patients were alopecia (28.3%), fatigue (26.1%), and peripheral sensory neuropathy (23.9%). Sixteen patients (34.8%) experienced grade ≥3 TRAEs; anemia and decreased neutrophil count occurred in ≥1 patient (both n = 2; 4.3%). CONCLUSION EV demonstrated antitumor activity in heavily pretreated HNC. Safety was consistent with the known safety profile of EV; no new safety signals were identified. These data support further evaluation of EV for advanced HNC not amenable to definitive local therapy.
Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay
Authors: Tristan Tay, Gayathri Bommakanti, Elizabeth Jaensch, Aparna Gorthi, Iswarya Karapa Reddy, Yan Hu, Ruochi Zhang, Aatman S Doshi, Sin Lih Tan, Verena Brucklacher-Waldert, Laura Prickett, James Kurasawa, Michael Glen Overstreet, Steven Criscione, Jason Daniel Buenrostro, Deanna A Mele
Journal: Cell Reports Medicine (2024)
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Authors: Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin, Florent Amatore, Julie S Deutsch, Rodrigo X Das Neves, Richard R Rodrigues, John A McCulloch, Hong Wang, Douglas J Hartman, Jonathan H Badger, Miriam R Fernandes, Yulong Bai, Jie Sun, Alicia M Cole, Poonam Aggarwal, Jennifer R Fang, Christopher Deitrick, Riyue Bao, Umamaheswar Duvvuri, Shaum S Sridharan, Seungwon W Kim, Haroon A Choudry, Matthew P Holtzman, James F Pingpank, James Patrick O'Toole, Richelle DeBlasio, Yang Jin, Quanquan Ding, Wentao Gao, Christopher Groetsch, Ornella Pagliano, Amy Rose, Corey Urban, Jagjit Singh, Prajan Divarkar, David Mauro, Dmitri Bobilev, James Wooldridge, Arthur M Krieg, Matthew G Fury, Jeffrey R Whiteaker, Lei Zhao, Amanda G Paulovich, Yana G Najjar, Jason J Luke, John M Kirkwood, Janis M Taube, Hyun Jung Park, Giorgio Trinchieri, Hassane M Zarour
Journal: Cancer Cell (2024)

Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR was associated with necrosis, and melanophagocytosis with increased CD8
Genetics of Latin American Diversity Project: Insights into population genetics and association studies in admixed groups in the Americas
Authors: Victor Borda, Douglas P Loesch, Bing Guo, Roland Laboulaye, Diego Veliz-Otani, Jennifer N French, Thiago Peixoto Leal, Stephanie M Gogarten, Sunday Ikpe, Mateus H Gouveia, Marla Mendes, Gonçalo R Abecasis, Isabela Alvim, Carlos E Arboleda-Bustos, Gonzalo Arboleda, Humberto Arboleda, Mauricio L Barreto, Lucas Barwick, Marcos A Bezzera, John Blangero, Vanderci Borges, Omar Caceres, Jianwen Cai, Pedro Chana-Cuevas, Zhanghua Chen, Brian Custer, Michael Dean, Carla Dinardo, Igor Domingos, Ravindranath Duggirala, Elena Dieguez, Willian Fernandez, Henrique B Ferraz, Frank Gilliland, Heinner Guio, Bernardo Horta, Joanne E Curran, Jill M Johnsen, Robert C Kaplan, Shannon Kelly, Eimear E Kenny, Barbara A Konkle, Charles Kooperberg, Andres Lescano, M Fernanda Lima-Costa, Ruth J F Loos, Ani Manichaikul, Deborah A Meyers, Michel S Naslavsky, Deborah A Nickerson, Kari E North, Carlos Padilla, Michael Preuss, Victor Raggio, Alexander P Reiner, Stephen S Rich, Carlos R Rieder, Michiel Rienstra, Jerome I Rotter, Tatjana Rundek, Ralph L Sacco, Cesar Sanchez, Vijay G Sankaran, Bruno Lopes Santos-Lobato, Artur Francisco Schumacher-Schuh, Marilia O Scliar, Edwin K Silverman, Tamar Sofer, Jessica Lasky-Su, Vitor Tumas, Scott T Weiss, Ignacio F Mata, Ryan D Hernandez, Eduardo Tarazona-Santos, Timothy D O'Connor
Journal: Cell Genomics (2024)
Procoagulant, antibacterial and antioxidant high-strength porous hydrogel adhesives in situ formed via self-gelling hemostatic microsheets for emergency hemostasis and wound repair
Authors: Yingli Shan, Feng Cao, Xin Zhao, Jinlong Luo, Haoliang Mei, Limou Zhang, Ying Huang, Yutong Yang, Liangruijie Yan, Yayong Huang, Yong Han, Baolin Guo
Journal: Biomaterials (2024)
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial
Authors: Steven Perrin, Shafeeq Ladha, Nicholas Maragakis, Michael H. Rivner, Jonathan Katz, Angela Genge, Nicholas Olney, Dale Lange, Daragh Heitzman, Cynthia Bodkin, Omar Jawdat, Namita A. Goyal, Jeffrey D. Bornstein, Carmen Mak, Stanley H. Appel, Sabrina Paganoni
Journal: PLoS Medicine (2024)

The interaction of CD40L and its receptor CD40 on activated T cells and B cells respectively control pro-inflammatory activation in the pathophysiology of autoimmunity and transplant rejection. Previous studies have implicated signaling pathways involving CD40L (interchangeably referred to as CD154), as well as adaptive and innate immune cell activation, in the induction of neuroinflammation in neurodegenerative diseases. This study aimed to assess the safety, tolerability, and impact on pro-inflammatory biomarker profiles of an anti CD40L antibody, tegoprubart, in individuals with amyotrophic lateral sclerosis (ALS).
The modified Baveno classification for obstructive sleep apnoea - Development and evaluation based on the ESADA database
Authors: Sandhya Matthes, Marcel Treml, Ludger Grote, Jan Hedner, Ding Zou, Maria R. Bonsignore, Jean-Louis Pépin, Sébastien Bailly, Silke Ryan, Walter T. McNicholas, Sofia E. Schiza, Johan Verbraecken, Athanasia Pataka, Paweł Śliwiński, Özen K. Basoglu, Carolina Lombardi, Gianfranco Parati, Winfried J. Randerath
Journal: European Respiratory Journal (2024)

Background The “Baveno classification” replaced the apnoea hypopnoea index (AHI) with symptoms and comorbidities for treatment indication in obstructive sleep apnoea (OSA). This study evaluates a modified Baveno classification which adds a validated cardiovascular disease (CVD) risk score and acknowledges severe breathing disturbances. Method OSA patients from the European Sleep Apnoea Data Base (ESADA) were retrospectively allocated into CVD risk groups 1–3 based on SCORE-2 and the ESC guidelines. AHI ≥30 /h conferred strong treatment indication. When AHI was &lt;30/h, symptoms and CVD risk dictated allocation to weak, intermediate or strong treatment indication group. Change in Epworth Sleepiness Scale (ESS) and office systolic blood pressure (SBP) at follow-up (12–24 months) under positive airway pressure (PAP) were assessed. Results 8625 patients were analysed (29% female, age 56 [49;64] years, BMI 31.9 [28.4;36.3] kg·m −2 ). Treatment indication was weak in 501 (6%), intermediate in 2085 (24%) and strong in 6039 (70%). There was a continuous increase in age, SBP, C-reactive protein and glycosylated haemoglobin from weak to strong (p&lt;0.001). PAP prescription increased from 52% to 64% to 93% (weak to strong, p&lt;0.001). The change in ESS score was −2, −4 and −5, respectively (p&lt;0.001). Reductions of ≥3 mmHg of median SBP occurred when AHI was ≥30/h and in symptomatic patients with CVD risk levels&gt;1 when AHI was &lt;30/h. Conclusion This analysis provides supporting evidence for the key role of CVD risk assessment and severe breathing disturbances in the identification of OSA patients most likely to benefit from treatment.
Long-Term Benefits and Safety of Statins in Patients with Kidney Failure
Authors: Franco Wing Tak Cheng, Wanchun Xu, Sydney Chi Wai Tang, Eric Yuk Fai Wan
Journal: Journal of the American Society of Nephrology (2024)

Key Points Patients with kidney failure are at a higher risk of cardiovascular diseases, but the evidence for statin therapy remains inconclusive. The long-term benefits and risks of statin therapy in patients with kidney failure were analyzed using public electronic health records in Hong Kong. Statin therapy was associated with a lower risk of major cardiovascular diseases and all-cause mortality without a higher risk of major adverse events. Background Patients with kidney failure are at elevated risk of cardiovascular diseases. Although statins are commonly used to mitigate cardiovascular risk among the population with high risk, the evidence for initiating statin therapy among patients with kidney failure remains inconclusive. This study aimed to investigate the long-term benefits and risks associated with statin therapy in patients with kidney failure. Methods Using territory-wide public electronic health records in Hong Kong, 3019 statin-eligible individuals with kidney failure and elevated LDL cholesterol ≥100 mg/dl from January 2008 to December 2015 were included for analysis. The framework of target trial emulation was adopted to investigate the risk of the major cardiovascular diseases ( i.e ., a composite of myocardial infarction, heart failure, and stroke), all-cause mortality, and major adverse events ( i.e ., myopathies and liver dysfunction) between statin initiators and statin noninitiators. The pooled logistic model was used to obtain the hazard ratio for the outcomes of interest in both intention-to-treat (ITT) analysis and per-protocol (PP) analysis. Results Significant risk reduction associated with statin therapy (hazard ratio [95% confidence interval]) was observed for major cardiovascular diseases (ITT: 0.78 [0.62 to 0.98]; PP: 0.66 [0.50 to 0.87]) and all-cause mortality (ITT: 0.80 [0.68 to 0.95]; PP: 0.60 [0.48 to 0.76]). The standardized 5- and 10-year absolute risk reduction in PP analysis was 7% (3% to 11%) and 11% (4% to 18%), respectively. No significant risks for the major adverse events were observed. Conclusions Statin therapy was associated with lower risks of cardiovascular diseases and all-cause mortality in patients with kidney failure without a higher risk of major adverse events.
Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide-bond catalytic activity
Authors: Qingnian Liu, Jiniu Huang, Hao Ding, Yue Tao, Jinliang Nan, Changchen Xiao, Yingchao Wang, Rongrong Wu, Cheng Ni, Zhiwei Zhong, Wei Zhu, Jinghai Chen, Chenyun Zhang, Xiao He, Danyang Xiong, Xinyang Hu, Jian'an Wang
Journal: Journal of Clinical Investigation (2024)

Myocardial infarction (MI) is characterized by massive cardiomyocytes death and cardiac dysfunction, and effective therapies to achieve cardioprotection are sorely needed. Here we reported that flavin containing monooxygenase 2 (FMO2) level was markedly increased in cardiomyocytes both in ex vivo and in vivo models of ischemia injury. Genetic deletion of FMO2 resulted in reduced cardiomyocyte survival and enhanced cardiac dysfunction, whereas cardiomyocyte-specific FMO2 overexpression exerted a protective effect in infarcted rat hearts. Mechanistically, FMO2 inhibited the activation of endoplasmic reticulum (ER) stress-induced apoptotic proteins, including caspase 12 and C/EBP homologous protein (CHOP), by down-regulating unfolded protein response (UPR) pathway. Furthermore, we identified FMO2 as a chaperone that catalyzed disulfide-bond formation in unfolded/misfolded proteins through its GVSG motif. GVSG-mutated FMO2 failed to catalyze disulfide-bond formation and lost its protection against ER stress and cardiomyocyte death. Finally, we demonstrated the protective effect of FMO2 in human induced pluripotent stem cell–derived cardiomyocyte (hiPSC-CM) model. Collectively, this study highlights FMO2 as a key modulator of oxidative protein folding in cardiomyocytes and underscores its therapeutic potential for treating ischemic heart disease.
Leptin signaling maintains autonomic stability during severe influenza infection in mice
Authors: Andrés R. Muñoz-Rojas, Adam C. Wang, Lisa E. Pomeranz, Elizabeth L. Reizis, Heather W. Stout-Delgado, Ileana C. Miranda, Krishnan Rajagopalan, Tadiwanashe Gwatiringa, Roger R. Fan, Ahmad A. Huda, Neha Maskey, Roseline P. Olumuyide, Aryan S. Patel, Jeffrey M. Friedman, Diane Mathis, Kartik N. Rajagopalan
Journal: Journal of Clinical Investigation (2024)
Using Simulation to Optimize the Design of Adaptive Clinical Trials
Authors: Cal H. Robinson, Rulan S. Parekh, Brian H. Cuthbertson, Eddy Fan, Yongdong Ouyang, Anna Heath
Journal: Journal of the American Society of Nephrology (2024)

Robinson, Cal H.; Parekh, Rulan S.; Cuthbertson, Brian H.; Fan, Eddy; Ouyang, Yongdong; Heath, Anna Author Information
Gangrene on the finger tip of a long term smoker
Authors: Der-Jr Huang, Yi-Hsien Shih
Journal: BMJ (2024)

A man in his 40s presented to the dermatology outpatient department with a two month history of a painful black, gangrenous tip to his left middle finger, which initially had been dry but progressed to a serous discharge (fig 1). The patient reported a one month history of erythema, along with pain and mild numbness, of the finger tip before the gangrene had developed. No other fingers, or toes, were involved. The patient did not report any systemic disease or history of trauma. He was a current smoker with a 20 pack year history. Fig 1 Gangrene on tip of finger Key findings on examination included normal brachial pulses but reduced radial and ulnar pulses. Laboratory data showed normal coagulation and autoimmune profiles, with no evidence of cryoglobulinaemia or antiphospholipid syndrome. Duplex ultrasonography indicated patent artery flow without signs of proximal atherosclerotic disease. Angiography showed gradual tapering of the left ulnar artery with an abrupt termination at a distal branch of the left profunda brachii artery, along with decreased arterial flow and poor perfusion in the affected finger.
Intraosseous or Intravenous Vascular Access for Out-of-Hospital Cardiac Arrest
Authors: Mikael F. Vallentin, Asger Granfeldt, Thomas L. Klitgaard, Søren Mikkelsen, Fredrik Folke, Helle C. Christensen, Amalie L. Povlsen, Alberthe H. Petersen, Sofie Winther, Lea W. Frilund, Carsten Meilandt, Mathias J. Holmberg, Kristian B. Winther, Allan Bach, Thomas H. Dissing, Christian J. Terkelsen, Steffen Christensen, Line Kirkegaard Rasmussen, Lone R. Mortensen, Mads L. Loldrup, Thomas Elkmann, Anders G. Nielsen, Charlotte Runge, Elise Klæstrup, Jimmy H. Holm, Mikkel Bak, Lars-Gustav R. Nielsen, Mette Pedersen, Gunhild Kjærgaard-Andersen, Peter M. Hansen, Anne C. Brøchner, Erika F. Christensen, Frederik M. Nielsen, Christian G. Nissen, Jeppe W. Bjørn, Peter Burholt, Laust E.R. Obling, Sarah L.D. Holle, Lene Russell, Henrik Alstrøm, Søren Hestad, Tanja H. Fogtmann, Jens U.H. Buciek, Karina Jakobsen, Mette Krag, Michael Sandgaard, Birthe Sindberg, Lars W. Andersen
Journal: New England Journal of Medicine (2024)

Out-of-hospital cardiac arrest is a leading cause of death worldwide. Establishing vascular access is critical for administering guideline-recommended drugs during cardiopulmonary resuscitation. Both the intraosseous route and the intravenous route are used routinely, but their comparative effectiveness remains unclear.
<i>Notes from the Field: Trichophyton mentagrophytes</i> Genotype VII — New York City, April–July 2024
Authors: Jason Zucker, Avrom S. Caplan, Shauna H. Gunaratne, Stephanie M. Gallitano, John G. Zampella, Caitlin Otto, Rachel Sally, Sudha Chaturvedi, Brittany O’Brien, Gabrielle C. Todd, Priyanka Anand, Laura A.S. Quilter, Dallas J. Smith, Tom Chiller, Shawn R. Lockhart, Meghan Lyman, Preeti Pathela, Jeremy A.W. Gold
Journal: MMWR Morbidity and Mortality Weekly Report (2024)
metastatic
Authors: Tega Ebeye
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Low-Magnitude Mechanical Signals to Preserve Skeletal Health in Female Adolescents With Anorexia Nervosa
Authors: Amy D. DiVasta, Catherine Stamoulis, Clinton T. Rubin, Jenny Sadler Gallagher, Douglas P. Kiel, Brian D. Snyder, Catherine M. Gordon
Journal: JAMA Network Open (2024)

Malnourished adolescents and young adults with anorexia nervosa (AN) are at high risk for skeletal deficits.
Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine
Authors: Jiatong Ding, Shuhang Wang, Ning Li
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Differences in Drug Shortages in the US and Canada
Authors: Mina Tadrous, Katherine Callaway Kim, Inmaculada Hernandez, Scott D. Rothenberger, Joshua W. Devine, Tina B. Hershey, Lisa M. Maillart, Walid F. Gellad, Katie J. Suda
Journal: JAMA (2024)

Drug shortages are a persistent public health issue that increased during the COVID-19 pandemic. Both the US and Canada follow similar regulatory standards and require reporting of drug-related supply chain issues that may result in shortages. However, it is unknown what proportion are associated with meaningful shortages (defined by a significant decrease in drug supply) and whether differences exist between Canada and the US.
Understanding Drug Supply Shortages in the US and Canada
Authors: K. Jane Muir, Joseph S. Ross
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Modeling the Population Equity of Alzheimer Disease Treatments in the US
Authors: Patricia G. Synnott, Thomas Majda, Pei-Jung Lin, Daniel A. Ollendorf, Yingying Zhu, Stacey Kowal
Journal: JAMA Network Open (2024)

The arrival of new medications for Alzheimer disease (AD) has prompted efforts to measure their value using conventional cost-effectiveness analyses; however, these analyses focus on how much health improvement new medications generate per dollar spent. As AD disproportionately affects older adults, women, racial and ethnic minority individuals, and individuals with lower socioeconomic and educational levels, it is critical to also examine the health equity outcomes of treatment.
Addressing Bone Health in Adolescents With Anorexia Nervosa—No Bones About It
Authors: Jason M. Nagata, Seohyeong Lee, Amanda E. Downey
Journal: JAMA Network Open (2024)

Amy D. DiVasta, MD, MMSc; Catherine Stamoulis, PhD; Clinton T. Rubin, PhD; Jenny Sadler Gallagher, MPH; Douglas P. Kiel, MD, MPH; Brian D. Snyder, MD, PhD; Catherine M. Gordon, MD, MS